Debiopharm

Get funding

Debiopharm Group is a biopharmaceutical development specialist that in-licenses promising biologics and small molecule drug.

Use:
Date closing: -
Amount: 1M € - 5.0M €
Industry focus: Health;
Total budget: 150M €
Entity type: Venture Capital
Vertical focus: All
Website: https://www.debiopharm.com/

Status:
Open
Funding type: Grant;
Geographic focus:
Public/Private: Private
Stage focus: Seed;
Applicant target: Startup;

Add a Review Send question

Overview

The Swiss biopharmaceutical company, Debiopharm, is an independent biopharmaceutical company based in Switzerland with an ongoing commitment to develop tomorrow’s standard of care to cure cancer & infectious diseases and improve patient quality of life. Our main activities include drug development, drug manufacturing and digital health investment.

They invest in 3 main areas: Next Gen Pharma R&D, Clinical Trial Tech, and Digital Medicine, but their focus is on oncology.

Debiopharm has announced the launch of a new seed funding worth €150M. Their initial investment is < $ 1M, focusing on Pre-Seed / Seed stage. In the case of Series A, their initial investment can be in the range of $3M – 5M.

The fund plans to invest in up to 15 seed-stage startups annually, focusing on digital health and cancer care innovation. This move aims to transform pharmaceutical research and development by supporting early-stage companies and advancing digital solutions in cancer treatment.

Portfolio: Tune Insight, Neoroute, Genialis, Mika.

Last updated on 2023-10-05 10:28